Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin and Rituximab in Low Grade B-Cell NHL and CLL
NCT00026351Phase 2Completed
- Sponsor
- Pharmatech Oncology
- Start
- Dec 2000
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentostatin and rituximab in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Pharmatech Oncology. Primary endpoint: Response Rate. Started Dec 2000; status: completed.
02
Drugs
pentostatinrituximab
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00026351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026351.